ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 488

Increased Expression of TNF-α and PAD-2 in Human Monocytes Following Treatment with Protein Modified with Malondialdehyde-Acetaldehyde (MAA) and Citrulline

Logan M. Duryee1, Michael J. Duryee2, Dahn L Clemens1, Evan M. Ryan1, Carlos D. Hunter2, Lynell W. Klassen3, James R. O'Dell3, Daniel R. Anderson1, Ted R. Mikuls4 and Geoffrey M. Thiele1, 1University of Nebraska Medical Center, Omaha, NE, 2Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 3Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 4Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Macrophage, PAD and citrullination

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  We have previously shown that malondialdehyde-acetaldehyde (MAA) and citrullinated proteins are present together in the synovial tissues of rheumatoid arthritis (RA) patients.  Macrophage are a major source of not only TNF-α, but also PAD enzymes and are both involved in the progression of RA.  MAA adducts and citrullinated proteins alone have the ability to increase TNF-α release in many different cell types.   Therefore, the objective of this study was to determine if proteins modified with both MAA and citrulline increase the expression and secretion of both PAD and TNF-α in a human monocytic cell line. 

Methods: THP-1 cells were grown and activated with PMA.  Following serum starvation the cells were incubated with either 50 µg/ml of human albumin (ALB), ALB-MAA, ALB-Citrulline (CIT) and ALB-MAA-CIT for 4 hours. Supernatants were collected and assayed for TNF-α protein by a commercial ELISA kit.   RNA was extracted from the cells and subjected to RT-PCR for expression of PAD-2, PAD-4, and TNF-α.

Results: Human monocytic cells exposed to ALB-MAA significantly increased levels of TNF-α protein from 35.5 ± 0.75 pg/ml to 146.8 ± 33.55 pg/ml compared to ALB alone (P<0.01) (A).  The addition of ALB-MAA-CIT significantly increased the secretion 435.5 ± 17.88 pg/ml (P<0.001) when compared to ALB-MAA (A).  Cells incubated with ALB-MAA-CIT showed and increased expression of TNF-α mRNA by 6 fold (698.6 ± 96.62 RQ) compared to MAA-ALB (20.09 ± 6.48 RQ) (P<0.001) (B). PAD-2 mRNA was increased following exposure to both ALB-MAA (1.79 ± 0.96 RQ) and ALB-MAA-CIT (4.87 ± 1.71 RQ) (compared to each other (P<0.05), although only the latter achieved statistical significance compared to ALB alone (P<0.02) (C).  No increase in PAD-4 mRNA was detected in any of the groups. Additionally, results from the stimulation by ALB-CIT were not different that ALB alone.

Conclusion:   We and others have shown that MAA-modified proteins and citrullinated proteins alone can activate macrophages to release TNF-α.  Until now, no studies have reported on the effects of these modified protein moieties commonly found in RA.  The significantly increased expression of TNF-α and PAD-2 mRNA in human macrophages following exposure to ALB-MAA-CIT, supported by the clinical observation that these protein(s) are found together in synovial tissues strongly suggests a role in the pathogenesis of RA.


Disclosure: L. M. Duryee, None; M. J. Duryee, None; D. L. Clemens, None; E. M. Ryan, None; C. D. Hunter, None; L. W. Klassen, None; J. R. O'Dell, Medac, 5,Coherus, 5; D. R. Anderson, None; T. R. Mikuls, BMS, 2,Ironwood Pharm, 2,Pfizer Inc, 5,NIH, VA, 2; G. M. Thiele, None.

To cite this abstract in AMA style:

Duryee LM, Duryee MJ, Clemens DL, Ryan EM, Hunter CD, Klassen LW, O'Dell JR, Anderson DR, Mikuls TR, Thiele GM. Increased Expression of TNF-α and PAD-2 in Human Monocytes Following Treatment with Protein Modified with Malondialdehyde-Acetaldehyde (MAA) and Citrulline [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/increased-expression-of-tnf-%ce%b1-and-pad-2-in-human-monocytes-following-treatment-with-protein-modified-with-malondialdehyde-acetaldehyde-maa-and-citrulline/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-expression-of-tnf-%ce%b1-and-pad-2-in-human-monocytes-following-treatment-with-protein-modified-with-malondialdehyde-acetaldehyde-maa-and-citrulline/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology